Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04808908 · ClinicalTrials.gov registry record · Phase 1
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04808908 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 10 participants.
The verdict
NCT04808908, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir. However, a concern is that CD8 T cells may be excluded from the B cell follicles, where a significant part of the reservoir resides. Webb, et al, has shown that in SIV infected monkeys CD8 T cells in follicles increase in frequency when N-803 is administered. We hypothesize that in HIV infected humans treated with N-803 that CD8 T cells will increase in B cell follicles and that there will be a further reduction in the frequency of cells with an inducible provirus.
Interventions
- BIOLOGICAL N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04808908
The ClinicalTrials.gov registry entry for NCT04808908 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-803 is the first listed.
NCT04808908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04808908 about?
NCT04808908 is a clinical study titled "Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease". N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir. However, a concern is that CD8 T cells may be excluded from the B cell follicles, where a significant part of the reservoir resides. Webb, et al, has...
What is the current status of trial NCT04808908?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-04-01. Estimated completion is 2023-01-01.
What interventions are being tested in trial NCT04808908?
The interventions under investigation include: N-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04808908?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.